"The cost of biotech comes from the risk associated with developing a therapeutic and the expense of managing clinical trials. Anyone who does not account for that, and the time it takes to go through regulatory procedures is just misguided. Yes the costs have come down (they always do), but the regulatory burden and risk are not going away anytime soon." - Deepak Singh